All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
The vector of anti-c-Met chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target Human c-Met. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-c-Met antibody linked to CD28 and CD3ζ signaling domains. And the vector product was designed for the treatment of Breast cancer.
CAR Construction : Fig.1 mAb OptD 11 binding to ceil surface c-Met in different tumor cells. |
CAR Construction : Fig.2 A binding curve for soluble c-Met ECD-Fc fusion protein by solid-phase ELISA. A binding curve for soluble c-Met ECD-Fc fusion protein by solid-phase ELIS A using the anti-c-Met therapeutic antibody C8-H241 (human IgG4 subtype) as a c-Met capture antibody and biotinylated mAb OptD 1 1 (murine IgGl subtype) as a c-Met detection antibody reagent. |
CAR Construction : Fig.3 the simultaneous but non-competitive binding of mAb C8- H241 (human IgG4 subtype) and OptD 11 to human c-Met-ECD-Fc-Flis fusion protein. |
More Published Data More Published Data
There are currently no customer reviews or questions for Anti-c-Met (XHM23) h(CD28-CD3ζ) CAR, pCDCAR1 (CAR-0120ZP3701). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION